Article info
PDFArchimedes
Question 2: Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?
- Correspondence to Harriet Hunter, School of Clinical Medicine, University of Cambridge, Cambridge CB5 8BL, UK; harriethunter95{at}gmail.com
Citation
Question 2: Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?
Publication history
- Received May 15, 2018
- Revised August 22, 2018
- Accepted August 28, 2018
- First published September 27, 2018.
Online issue publication
October 18, 2018
Article Versions
- Previous version (27 September 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.